본문 바로가기
  • 학술저널

표지

DBpia에서 서비스 중인 논문에 한하여 피인용 수가 반영됩니다. 내서재에 논문을 담은 이용자 수의 총합입니다.

발행기관의 요청으로 개인이 구매하실 수 없습니다.

초록·키워드 목차

Fenofibrate is one of PPAR-α (peroxisome proliferator activated receptor alpha) agonists. Fenofibrate decreases effectively triglycerideand increases high density lipoprotein cholesterol level through the effect on lipoprotein lipase, hepatic production anddegradation of lipoproteins. Fenofibrate was recommended as the drug for hypertriglyceridemia treatment in European guideline releasedin 2011. But American heart association guideline in 2013 did not recommend non-statin therapy including fibrate for theprevention of atherosclerotic cardiovascular disease. But fenofibrate is still considered as the important drug for the management ofatherogenic dyslipidemia especially in patients with metabolic syndrome and diabetes to reduce the residual risk after statin therapyfrom the evidence of many studies. Fibrates including bezafibrate, gemfibrozil, and fenofibrate increased serum creatinine level inseveral studies. But the mechanism of change in renal function is not clear till now. And the reversibility of renal function with drugdiscontinuation is dependent on the kinds of fibrate. Fenofibrate increased serum creatinine level, decreased albuminuria and renalfunction was reversible with the drug discontinuation in large clinical trials. In these days renal function change with fenofibratetherapy in Korean patients with hypertriglyceridemia was investigated. Fenofibrate treatment for 2 months increased serum creatininelevel significantly and old age was associated with the change of renal function in multivariate analysis. Short-term therapysignificantly increased serum creatinine level even within normal range, and this change may be important in some groups especiallyold age. #페노피브레이트 #크레아티닌 #사구체 여과율 #Fenofibrate #Creatinine #Glomerular filtration rate

등록된 정보가 없습니다.

DBpia에서 서비스 중인 논문에 한하여 피인용 수가 반영됩니다.
Insert title here
논문의 정보가 복사되었습니다.
붙여넣기 하세요.